shaped relationship to weight (BMI) indicating potential cost offsets by effective weight-loss intervention.

**CARDIOVASCULAR DISEASES/DISORDERS—Clinical Outcomes**

**PCV37**

**DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?**

Gwadry-Sridhar F1, Arnold M1, Weaver B1, Guyatt G1
1McMaster University, London, ON, Canada; 2London Health Sciences Centre, London, ON, Canada

**OBJECTIVES:** Patients with Heart Failure (HF) are known to have poor compliance even with medications that can help reduce mortality and events such as readmissions. We wanted to examine whether compliance with three such medications, primarily ACE-Inhibitors, Digoxin and Spironolactone would have any impact on the time to an event in HF patients. An event was defined as a readmission to hospital, an emergency room visit following a discharge from the index admission or death.

**METHODS:** Patients with HF who were admitted to the London Health Sciences Centre were stratified then randomized to receive either usual care education (U) or an enhanced educational intervention (I) aimed at improving compliance that was delivered in hospital, prior to discharge. Compliance data was collected from pharmacy refill data from baseline over the period of follow-up that was 12 months. A Cox Regression time-to-event analysis was run for all patients adjusting for randomization ARM and then adjusting for the covariates of interest, the minimum and mean compliance. **RESULTS:** Seventy-five out of 134 patients had an event. There was no difference in time to event by ARM. The inclusion of the minimum and mean compliance of each drug individually in the regression did not result in any significant changes in the time-to-event; however, there was a trend $p = 0.082$ in patients who were on spironolactone and had compliance $<0.80$. **CONCLUSIONS:** We can hypothesize that there may be a differential effect on the time to an event in this population depending upon the medication. We should be careful not to group all medication compliance into one composite number as different medications in HF have different effects on survival. This data warrants a more careful assessment of compliance for each HF medication and a determination of its effect on clinical outcomes of interest.

**PCV38**

**LIPID LOWERING MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES**

Brophy J, Bourgault C, Brassard P
McGill University, Montreal, QC, Canada

**OBJECTIVES:** Clinical trials have demonstrated improved outcomes in patients receiving cholesterol lowering medications (CLM) following coronary revascularization and clinical guidelines recommend aggressive cholesterol lowering therapy for patients with established coronary disease. However, in routine practice, the degree to which these recommendations are followed and their impact are unknown. **METHODS:** Using administrative databases, we examined the use of CLM in a consecutive cohort of 11,985 elderly (average age 71.4) patients undergoing coronary revascularization from 1995 until 1997 in Quebec, Canada. **RESULTS:** Before revascularization, 30.9% were receiving CLM. After a 3-year follow-up, 62.8% of cohort survivors had received at least 1 prescription for CLM. CABG patients had a decreased probability of receiving CLM compared to PCI patients (OR .75 95% CI .72-.79). High-risk patients especially the very elderly (>75) had a significantly decreased probability of receiving CLM (OR .61 95% CI .57-.66). The most potent predictor of a post-operative prescription use was pre-operative utilization (OR 7.1 95% CI 6.8–7.5). An adjusted time-dependent analysis showed that patients receiving CLM had a lower risk of death (RR 0.61 95% CI 0.52–0.79) or myocardial infarction (RR 0.78 95% CI 0.64–0.93) than those not exposed to these drugs. There was no difference in the need for a repeat revascularization between the groups (RR 1.05 95% CI 0.91–1.20). **CONCLUSIONS:** CLM were underused in this post revascularization population and this underuse was associated with an increase in adverse outcomes.

**PCV39**

**A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION**

Richard LJ, Howard PA, Thorpe T
Heron Evidence Development LTD, Stevenage, United Kingdom

Pulmonary arterial hypertension (PAH) is a rare, incurable and often fatal disorder of the lung in which pulmonary artery pressure rises to abnormal levels. It may either be idiopathic in nature (primary pulmonary hypertension) or a manifestation of many different disorders (secondary pulmonary hypertension). Current management includes prostacyclin vasodilator therapy, and conventional therapy consisting of calcium channel blockers, anticoagulation, oxygen therapy and diuresis; and newer agents such as bosentan, an endothelin antagonist. To date, no systematic review has assessed these interventions. **OBJECTIVES:** To perform a systematic review of the medical interventions used in the management of PAH. **METHODS:** A literature search of EMBASE and MEDLINE was performed, and studies matching the pre-defined inclusion criteria extracted to HTA-standardised grids and graded using the Jadad score. Data for three outcome measures survival, exercise capacity and right